EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.68, no.5, pp.629-636, 2012 (SCI-Expanded)
Article / Article
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Science Citation Index Expanded (SCI-EXPANDED), Scopus
Lansoprazole, CYP2C19, Phenotyping, Genotyping, Children, S-MEPHENYTOIN OXIDATION, PROTON PUMP INHIBITORS, CYP2C19-ASTERISK-17 ALLELE, GENETIC POLYMORPHISMS, CYP2C19 ACTIVITY, BREATH TEST, PROGUANIL METABOLISM, DRUG-METABOLISM, OMEPRAZOLE, PHARMACOKINETICS
Hacettepe University Affiliated:
Lansoprazole, a cytochrome P450 2C19 (CYP2C19) substrate, has been widely used in children to manage acid-related diseases. CYP2C19 exhibits marked genetic polymorphisms, and distribution of these polymorphisms varies among different ethnic groups. There is limited data regarding the use of probe drugs for determining CYP2C19 activity in children. The aim of this study was to evaluate lansoprazole as an in vivo phenotyping probe for assessing CYP2C19 activity in children.